The recommendation of the Committee will be considered by the FDA it validates the it validates the New Drug Application for ceftaroline , mainly based on data from two Phase III clinical trials in CABP FOCUS I and FOCUS II – and two Phase 3 trials in cSSSI – CANVAS I and CANVAS II Japan where expects actions by the FDA in the fourth quarter.
The primary treatment for CABP is antibiotics, and the increased rates of resistance to many common antibiotics. Pneumoniae accounts for 60 % to 70 % of all bacterial CABP cases and data have shown hospitalization pneumococcal isolates a 28 % intermediate resistance layer and a rate of 16 % high-level resistance rate was. With increasing rates of pneumonia caused by MRSA and high resistance to common antibiotics treatment options always limited.NotesAbout ExpertControl Review of Respiratory MedicineISSN:. 1747-6348, strip: Quantity 5 , rate 6 issues per yearspecificationExpert Review of Respiratory Medicine offers analyzed and structured commentary by international executives in the fields obstructive, restrictive vascular and infectious diseases, respiratory disorders.